Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

被引：11

作者：

Al-Batran, Salah-Eddin ^{[1
,3
]}

Hofheinz, Ralf-Dieter ^{[2
]}

Reichart, Alexander ^{[1
,3
]}

Pauligk, Claudia ^{[3
]}

Schoenherr, Caroline ^{[3
]}

Schlag, Rudolf ^{[4
]}

Siegler, Gabriele ^{[5
]}

Doerfel, Steffen ^{[6
]}

Koenigsmann, Michael ^{[7
]}

Zahn, Mark-Oliver ^{[8
]}

Schubert, Joerg ^{[9
]}

Aldaoud, Ali ^{[10
]}

Hoeffkes, Heinz-Gert ^{[11
,12
]}

Schulz, Holger ^{[13
]}

Hahn, Lars ^{[14
]}

Uhlig, Jens ^{[15
]}

Blau, Wolfgang ^{[16
]}

Stauch, Martina ^{[17
]}

Weniger, Joerg ^{[18
]}

Wolf, Martin ^{[19
]}

Jacobasch, Lutz ^{[20
]}

Bildat, Stephan ^{[21
,22
]}

Wehmeyer, Juergen ^{[23
]}

Homann, Nils ^{[24
]}

Trojan, Joerg ^{[25
]}

Waidmann, Oliver ^{[25
]}

Fietz, Thomas ^{[26
]}

Feustel, Hans-Peter ^{[27
]}

Groschek, Matthias ^{[28
]}

Wierecky, Jan ^{[29
]}

Waibel, Karin ^{[30
]}

Mahlmann, Stefan ^{[31
]}

Schwindel, Uwe ^{[32
]}

Peters, Uwe ^{[33
]}

Schuch, Gunter ^{[34
]}

Pink, Daniel ^{[35
,36
]}

Eschenburg, Henning ^{[37
]}

Woerns, Marcus-A. ^{[38
]}

Harich, Hans-Detlev ^{[39
]}

von Weikersthal, Ludwig Fischer ^{[40
]}

Daessler, Klaus-Ulrich ^{[41
]}

Behringer, Dirk M. ^{[42
]}

Messmann, Helmut ^{[43
]}

Kretzschmar, Albrecht ^{[44
]}

Gallmeier, Eike ^{[45
]}

Forstbauer, Helmut ^{[46
]}

Kunzmann, Volker ^{[47
]}

Papke, Jens ^{[48
]}

Buechner-Steudel, Petra ^{[49
]}

Vehling-Kaiser, Ursula ^{[50
]}

机构：

[1] UCT Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany

[2] Univ Med Mannheim, Interdisziplinares Tumorzentrum, Mannheim, Germany

[3] Krankenhaus NW Frankfurt, Inst Klin Krebsforsch IKF GmbH, Frankfurt, Germany

[4] Gemeinschaftspraxis Schlag Schottker, Wurzburg, Germany

[5] Klinikum Nurnberg PMU, Nurnberg, Germany

[6] Onkozentrum Dresden, Dresden, Germany

[7] MediProjekt GbR, Hannover, Germany

[8] MVZ Onkol Kooperat Harz, Goslar, Germany

[9] Elblandklinikum Riesa, Riesa, Germany

[10] HELIOS Pk Klinikum, Pankreaszentrum Leipzig, Leipzig, Germany

[11] Univ Med Marburg, Klinikum Fulda, Fulda, Germany

[12] MVZ Osthessen GmbH, Fulda, Germany

[13] Pioh Frechen Koln Praxis Internist Onkol & Hamato, Frechen, Germany

[14] Dokusan Gesell Med Studien GmbH & Co KG, Herne, Germany

[15] Hamatol Onkol Schwerpunktpraxis, Naunhof, Germany

[16] Univ Klinikum Giessen & Marburg, Med Klin 4 5, Giessen, Germany

[17] Schwerpunktpraxis Hamatol Onkol, Kronach, Germany

[18] Gemeinschaftspraxis Hamatol & Onkol Dres Wenige B, Erfurt, Germany

[19] Klinikum Kassel GmbH, Klin Hamatol & Onkol, Kassel, Germany

[20] Onkol Gemeinschaftspraxis Dr Med Lutz Jacobasch, Dresden, Germany

[21] Klinikum Herford, Med Klin 2, Herford, Germany

[22] Onkol Zentrum, MVZ Onkol, Herford, Germany

[23] Gemeinschaftspraxis Hamatol & Onkol, Munster, Germany

[24] Klinikum Wolfsburg, Med Klin 2, Wolfsburg, Germany

[25] Klinikum JW Goethe Univ Frankfurt, Frankfurt, Germany

[26] Schwerpunktpraxis Hamatol, Onkol & Gastroenterol Dres Banhardt Fietz Hertkor, Singen, Germany

[27] Onkol Schwerpunktpraxis Speyer, Speyer, Germany

[28] Clin Res Stolberg GmbH, Stolberg, Germany

[29] Schwerpunkt Hamatol Onkol & Palliativmed, Uberortliche Gemeinschaftspraxis, Hamburg, Germany

[30] Medius Kliniken gGmbH, Medius Klin Ostfildern Ruit, Ostfildern Ruit, Germany

[31] Westpfalz Klinikum GmbH, Kaiserslautern, Germany

[32] GPR Gesundheits & Pflegezentrum gGmbH, Med Klin 1, Russelsheim, Germany

[33] Ambulantes Tumorzentrum Spandau Dres Peters & Sae, Berlin, Germany

[34] Hamatol Onkol Praxis Altona HOPA, Hamburg, Germany

[35] Ernst Moritz Arndt Univ Greifswald, Klin & Poliklin Innere Med C, Hamatol & Onkol, Transplantationszentrum,Palliativmed, Greifswald, Germany

[36] HELIOS Klinikum Bad Saarow, Sarkomzentrum Berlin Brandenburg, Klin Hamatol Onkol & Palliativmed, Brandenburg, Germany

[37] Internist Gemeinschaftspraxis Dres, Gustrow, Germany

[38] Univ Med Mainz, Med Klin & Poliklin 1, Mainz, Germany

[39] Onkol Hof MVZ Dres Kasper Harich, Hof, Germany

[40] Gesundheitszentrum St Marien GmbH, Praxis Hamatol & Internist Onkol, Amberg, Germany

[41] Praxis Dipl Med Klaus Ulrich Dassler, Freital, Germany

[42] Augusta Kranken Anstalt gGmbH, Bochum, Germany

[43] Univ Klinikum Augsburg, Med Klin 3, Augsburg, Germany

[44] MVZ Mitte Onkol Schwerpunktpraxis, Leipzig, Germany

[45] Univ Klinikum Giessen & Marburg GmbH, Klin Innere Med, Marburg, Germany

[46] GOSPL Gesell Onkol Studien, Troisdorf, Germany

[47] Univ Klin Wurzburg, Zentrum Innere Med, Med Klin & Poliklin 2, Wurzburg, Germany

[48] Praxis Prof Dr Med Jens Papke, Neustadt, Germany

[49] Univ Klinikum Halle Saale, Klin & Poliklin Innere Med 1, Halle, Germany

[50] VK&K Studien GbR, Landshut, Germany

来源：

INTERNATIONAL JOURNAL OF CANCER | 2021年 / 148卷 / 06期

关键词：

chemotherapy; pancreatic cancer; PARAGON; QOLIXANE; quality of life; registry; PLUS GEMCITABINE; SURVIVAL; FOLFIRINOX; IMPACT; THERAPY; MPACT;

D O I：

10.1002/ijc.33336

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Few data exist on health-related quality of life (QoL) in patients with metastatic pancreatic cancer (mPC) receiving first-line chemotherapy (Awad L ZE, Mesbah M Boston, MA. Applying survival data methodology to analyze quality of life data, in Mesbah M, Cole BF, Ting Lee M-L (eds): Statistical Methods for Quality of Life Studies: Design, Measurements and Analysis. Kluwer Academic Publishers 2002). The QOLIXANE study is a prospective, noninterventional, multicenter substudy of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer (PARAGON) registry, which evaluated QoL in patients with mPC receiving first-line gemcitabine and nab-paclitaxel chemotherapy in real-life setting. QoL was prospectively measured via EORTC QLQ-C30 questionnaires at baseline and every month thereafter. Therapy and efficacy parameters were prospectively collected. Main objectives were the rate of patients without deterioration of Global Health Status/QoL (GHS/QoL) at 3 and 6 months. Six hundred patients were enrolled in 95 German study sites. Median progression-free survival was 5.9 months (95% confidence interval [CI], 5.2-6.3). Median overall survival (OS) was 8.9 months (95% CI, 7.9-10.2), while median time to deterioration of GHS/QoL was 4.7 months (95% CI, 4.0-5.6). With a baseline GHS/QoL score of 46 (SD, 22.8), baseline QoL of the patients was severely impaired, in most cases due to loss in role functioning and fatigue. In the Kaplan-Meier analysis, 61% and 41% of patients had maintained GHS/QoL after 3 and 6 months, respectively. However, in the QoL response analysis, 35% and 19% of patients had maintained (improved or stable) GHS/QoL after 3 and 6 months, respectively, while 14% and 9% had deteriorated GHS/QoL with the remaining patients being nonevaluable. In the Cox regression analysis, GHS/QoL scores strongly predicted survival with a hazard ratio of 0.86 (P < .0001). Patients with mPC have poor QoL at baseline that deteriorates within a median of 4.7 months. Treatment with gemcitabine and nab-paclitaxel is associated with maintained QoL in relevant proportions of patients. However, overall, results remain poor, reflecting the aggressive nature of the disease.

引用

页码：1478 / 1488

页数：11

共 50 条

[41] Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer
Sherrill, Beth
Di Leo, Angelo
Amonkar, Mayur M.
Wu, Yun
Zvirbule, Zanete
Aziz, Zeba
Bines, Jose
Gomez, Henry L.
CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (04) : 767 - 775
[42] A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
Bachet, Jean-Baptiste
Chibaudel, Benoist
Bonnetain, Franck
Validire, Pierre
Hammel, Pascal
Andre, Thierry
Louvet, Christophe
BMC CANCER, 2015, 15
[43] Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
Palumbo, Raffaella
Sottotetti, Federico
Trifiro, Giuseppe
Piazza, Elena
Ferzi, Antonella
Gambaro, Anna
Spinapolice, Elena Giulia
Pozzi, Emma
Tagliaferri, Barbara
Teragni, Cristina
Bernardo, Antonio
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2189 - 2199
[44] Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
Yalcin, Suayib
Dane, Faysal
Oksuzoglu, Berna
Ozdemir, Nuriye Yildirim
Isikdogan, Abdurrahman
Ozkan, Metin
Demirag, Guzin Gonullu
Coskun, Hasan Senol
Karabulut, Bulent
Evrensel, Turkkan
Ustaoglu, Mehmet Ali
Ozdemir, Feyyaz
Turna, Hande
Yavuzsen, Tugba
Aykan, Faruk
Sevinc, Alper
Akbulut, Hakan
Yuce, Deniz
Hayran, Mutlu
Kilickap, Saadettin
BMC CANCER, 2020, 20 (01)
[45] On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting
Lazzaro, Carlo
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
[46] Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results
Carrato, Alfredo
Maria Vieitez, Jose
Benavides, Manuel
Rodriguez-Garrote, Mercedes
Castillo, Alfredo
Duran Ogalla, Gema
Bermejo, Laura Garcia
Ruiz de Mena, Inmaculada
Guillen-Ponce, Carmen
Aranda, Enrique
EUROPEAN JOURNAL OF CANCER, 2020, 139 : 51 - 58
[47] Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
Schwartzberg, Lee
McIntyre, Kristi
Wilks, Sharon
Puhalla, Shannon
O'Shaughnessy, Joyce
Berrak, Erhan
He, Yaohua
Vahdat, Linda
BMC CANCER, 2019, 19 (1)
[48] Efficacy and quality of life for FOLFOX/bevacizumab plus /- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial
Schmoll, Hans-Joachim
Mann, Julia
Meinert, Fabian
Garlipp, Benjamin
Borchert, Kersten
Vogel, Arndt
Goekkurt, Eray
Kaiser, Ulrich
Hoeffkes, Heinz-Gert
Ruessel, Joern
Kanzler, Stephan
Edelmann, Thomas
Forstbauer, Helmut
Goehler, Thomas
Hannig, Carla
Hildebrandt, Bert
Roll, Carsten
Bokemeyer, Carsten
Steighardt, Joerg
Cygon, Franziska
Ibach, Stefan
Stein, Alexander
Tintelnot, Joseph
BRITISH JOURNAL OF CANCER, 2024, 130 (02) : 233 - 241
[49] Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)
Park, Yeon Hee
Jung, Kyung Hae
Im, Seock-Ah
Sohn, Joo Hyuk
Ro, Jungsil
Ahn, Jin-Hee
Kim, Sung-Bae
Nam, Byung-Ho
Oh, Do Youn
Han, Sae-Won
Lee, Soohyeon
Park, In Hae
Lee, Keun Seok
Kim, Jee Hyun
Kang, Seok Yun
Lee, Moon Hee
Park, Hee Sook
Woo, Sook Young
Jung, Sin-Ho
Ahn, Jin Seok
Im, Young-Hyuck
BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (01) : 77 - 85
[50] The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial
Leinert, Elena
Singer, Susanne
Janni, Wolfgang
Harbeck, Nadia
Weissenbacher, Tobias
Rack, Brigitte
Augustin, Doris
Wischnik, Arthur
Kiechle, Marion
Ettl, Johannes
Fink, Visnja
Schwentner, Lukas
Eichler, Martin
CLINICAL BREAST CANCER, 2017, 17 (02) : 100 - 106

← 1 2 3 4 5 →